#Radioligand

2 stories

Research April 22, 2026 · View digest

AlphaGen's [212Pb]Pb-AG1206 Macrocyclic Peptide Radioligand Targets FAP in Solid Tumors

AlphaGen Therapeutics presented preclinical data at AACR 2026 (April 22) showing its novel macrocyclic peptide-based alpha-emitter radioligand [212Pb]Pb-AG1206 binds fibroblast activation protein with picomolar affinity, achieving rapid tumor accumulation, renal clearance, and a high tumor-to-kidney ratio. A sister candidate [212Pb]Pb-AG1002 targets SSTR2 as a non-agonist alpha therapy for neuroendocrine tumors.

Clinical Trials April 21, 2026 · View digest

Perspective Therapeutics' Alpha-Emitter PRRT Hits 43% ORR in Neuroendocrine Tumors at AACR

Perspective Therapeutics' [212Pb]VMT-α-NET, a first-in-class alpha-emitter peptide radionuclide therapy targeting SSTR2, achieved objective responses in 10 of 23 (43%) Cohort 2 patients with metastatic neuroendocrine tumors in Phase 1/2a data presented at AACR 2026. 18 of 25 patients (72%) remained alive without progression; no dose-limiting toxicities or Grade 4/5 adverse events observed.